Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study.

Duell J, Abrisqueta P, André M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AMarina, Maddocks KJ, Menne T, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023.